Radiopharm Theranostics Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K covers the reporting period of February 2026, specifically dated February 24, 2026. Radiopharm Theranostics Limited, a foreign private issuer based in Australia, filed this report to disclose a material corporate announcement made to the Australian Securities Exchange.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is an event-driven disclosure and does not contain financial statements or quantitative financial data.
Material Changes
The primary material event disclosed is the dosing of the first patient in the Company's 177Lu-BetaBart (RV-01) clinical study. This milestone represents a significant advancement in the Company's clinical development program.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard regulatory disclaimer. The report explicitly states that it shall not be deemed "filed" for purposes of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- First patient dosed in the 177Lu-BetaBart (RV-01) study on or before February 24, 2026.
- The study utilizes the RV-01 therapeutic agent.
- The announcement was originally published on the Australian Securities Exchange.
- No financial performance data is included in this specific filing.